Anastasis Biotec
Business Services · United Kingdom · 1-10 Employees
View Company Info for Free
Overview
Headquarters
56 Haverstock Hl, London, Greater London...Website
www.anastasisbiotec.comRevenue
<$5 MillionIndustry
About Anastasis Biotec
Is Anastasis Biotec your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Anastasis Biotec launches new products
Funding: Get notified immidiatlly once Anastasis Biotec has new funding data
Congratulate Masked Content for being promoted to Masked Content at Anastasis Biotec
Click to see if Anastasis Biotec had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Anastasis Biotec recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Anastasis Biotec, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Anastasis Biotec has recently received funding, and reach out quickly before it becomes old news!
Check out if Anastasis Biotec is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Anastasis Biotec
Compare insights from companies similar to Anastasis Biotec, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Anastasis Biotec
Anastasis Biotec Tech Stack
A closer look at the technologies used by Anastasis Biotec
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Anastasis Biotec
Anastasis Biotec is focused on developing a novel and proprietary cancer treatment that targets specific cancer-driving mutations. Their technology involves analyzing tumor tissue to identify critical mutations and treating selected patients with matching pathway inhibitors. The company is currently raising funds to conduct preclinical and clinical... Read More